Image de Google Jackets
Vue normale Vue MARC vue ISBD

Functional genomics and therapeutic innovations in T-cell acute lymphoblastic leukemia

Par : Contributeur(s) : Type de matériel : TexteTexteLangue : français Détails de publication : 2024. Ressources en ligne : Abrégé : T-cell acute lymphoblastic leukemias (T-ALL) account for 25% of adult ALL and 15% of pediatric ALL. Their prognosis, long considered more unfavorable than that of B-ALL, has improved significantly in recent years. However, a major challenge remains in this disease. Nearly 20% of patients will suffer a relapse, which is still associated with an extremely poor prognosis (less than 20% survival at 5 years.) While advances in molecular biology in recent years have led to the identification of a large number of potentially targetable alterations involved in T oncogenesis, the therapeutic arsenal for relapsed or refractory disease remains limited to date, and only a few innovative therapies have been developed. Unlike B-ALL, T-ALL has not benefited from the immunotherapy revolution, which has seen the development of bispecific antibodies and the advancement of chimeric antigen receptor T cells (CAR-T cells) for B hemopathies. There is therefore an urgent need to identify new therapeutic targets that will lead, in the short term, to the development of new therapies that are lacking in this disease. This review presents recent advances in the oncogenesis of T-ALL and discusses the potential therapeutic opportunities associated with them.
Tags de cette bibliothèque : Pas de tags pour ce titre. Connectez-vous pour ajouter des tags.
Evaluations
    Classement moyen : 0.0 (0 votes)
Nous n'avons pas d'exemplaire de ce document

62

T-cell acute lymphoblastic leukemias (T-ALL) account for 25% of adult ALL and 15% of pediatric ALL. Their prognosis, long considered more unfavorable than that of B-ALL, has improved significantly in recent years. However, a major challenge remains in this disease. Nearly 20% of patients will suffer a relapse, which is still associated with an extremely poor prognosis (less than 20% survival at 5 years.) While advances in molecular biology in recent years have led to the identification of a large number of potentially targetable alterations involved in T oncogenesis, the therapeutic arsenal for relapsed or refractory disease remains limited to date, and only a few innovative therapies have been developed. Unlike B-ALL, T-ALL has not benefited from the immunotherapy revolution, which has seen the development of bispecific antibodies and the advancement of chimeric antigen receptor T cells (CAR-T cells) for B hemopathies. There is therefore an urgent need to identify new therapeutic targets that will lead, in the short term, to the development of new therapies that are lacking in this disease. This review presents recent advances in the oncogenesis of T-ALL and discusses the potential therapeutic opportunities associated with them.

PLUDOC

PLUDOC est la plateforme unique et centralisée de gestion des bibliothèques physiques et numériques de Guinée administré par le CEDUST. Elle est la plus grande base de données de ressources documentaires pour les Étudiants, Enseignants chercheurs et Chercheurs de Guinée.

Adresse

627 919 101/664 919 101

25 boulevard du commerce
Kaloum, Conakry, Guinée

Réseaux sociaux

Powered by Netsen Group @ 2025